Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.66T
Revenue (ttm)	1.49T
Net Income (ttm)	75.10B
Shares Out	11.51M
EPS (ttm)	6,526.64
PE Ratio	22.11
Forward PE	11.24
Dividend	600.00 (0.42%)
Ex-Dividend Date	Dec 27, 2024

Volume	57,321
Average Volume	40,501
Open	142,300
Previous Close	142,100
Day's Range	141,100 - 148,900
52-Week Range	109,000 - 174,500
Beta	0.55
RSI	56.90
Earnings Date	Aug 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.